56 ± 4.35 0.335 −19.63 ± 4.10 8.69 86.55 5% UNP PLA-PCL-TPGS 198.46 ± 2.49 0.246 −18.29 ± 3.25 9.89 98.79 None TNP PLA-PCL-TPGS 206.15 ± 3.66 0.286 24.66 ± 4.19 9.79 97.56 5% PS-341 order DNP PLA-PCL-TPGS 219.33 ± 4.25 0.317 26.18 ± 5.02 9.88 98.55 20% PDI 3-MA polydispersity index; EE drug entrapment efficiency; n = 3. Regarding the drug EE, it can be seen from Table 1 that the 5% thiolated chitosan-modified PLA-PCL-TPGS nanoparticles achieved much higher EE than the 5% thiolated chitosan-modified PCL nanoparticles.

This might be contributed to the self-emulsification effect of TPGS segment in the PLA-PCL-TPGS copolymer [2, 8]. Surface morphology Surface morphology of the 5% thiolated chitosan-modified PLA-PCL-TPGS nanoparticles was inspected by FESEM. Figure 2 shows the FESEM image of 5% thiolated chitosan-modified PLA-PCL-TPGS nanoparticles. The FESEM image further confirmed the particle size determined by laser light scattering. The morphology of the nanoparticles exhibited well-formed spherical shape with rough surface. Figure 2 FESEM image of paclitaxel-loaded 5% thiolated Selleckchem Go6983 chitosan-modified PLA-PCL-TPGS nanoparticles. In vitro drug release assay The in vitro drug release profiles of the CNP, UNP, and TNP in the first 32 days are

presented in Figure 3. The drug release from the TNP was found to be 38.47% and 66.59% of the encapsulated drug in the first 5 days and after 32 days, respectively, which was much faster than the CNP, which was only 20.10% and 38.00%, respectively, in the same periods. The faster drug release of TNP may be attributed to the lower molecular weight and the higher hydrophilicity of PLA-PCL-TPGS copolymer click here in comparison

with the PCL nanoparticles. It causes the copolymer to swell and to degrade faster, thus promoting the drug release from the nanoparticles. It can also be seen from Figure 3 that drug release from the TNP was slightly slower than that of UNP. Such a phenomenon may be attributed to slightly smaller particle size of UNP. Figure 3 The in vitro release profiles of paclitaxel-loaded CNP, UNP, TNP. Uptake of coumarin-6-loaded nanoparticles by Caco-2 and A549 cells Caco-2 colonic cell line is a widely accepted model to predict the permeability and absorption of compounds in humans [38]. Paclitaxel (Taxol) has been shown to be effective in metastatic lung cancer as a single agent and in combination with other cytotoxic drugs. The fluorescence uptake by the A549 cells could provide a useful model to assess the in vitro therapeutic effect of paclitaxel in the various formulations for lung cancer treatment [39, 40]. The cellular uptake of coumarin-6-loaded CNP, UNP, and TNP was thus evaluated in this research using Caco-2 cell line as in vitro model of the GI barrier and A549 cell line as model cancer cells.